Natixis Advisors 13F: Cuts Cardinal Health (CAH) Stake by $6.8M

Natixis Advisors Trims Holdings in Cardinal Health

Natixis Advisors trimmed its investment in Cardinal Health, Inc. NYSECAH during the period, according to a Form 13F filing with the Securities and Exchange Commission. The filing reflects holdings as of the reporting period and may not represent the investor's current position. The firm sold 28,419 shares, marking a 5.4% reduction from its prior count. This left the fund with 492,832 shares of the healthcare provider.

Position Details and Prior Activity

Before this reduction, Natixis Advisors held 521,251 shares of the company. The remaining stake carried a value of about $117.1 million at the close of the reporting window. This sale follows similar adjustments by other institutional managers earlier in the year. For instance, HSBC Holdings reduced its position by 15.1% by cutting 92,629 shares, while Intech Investment Management trimmed its stake by 29.9% by shedding 62,358 shares. Lido Advisors also reduced its position by nearly 25%, holding 43,149 shares, and the California State Teachers Retirement System trimmed its holdings by 9,726 shares. On the other hand, funds like Janus Henderson Group moved in the opposite direction by boosting their investments over a similar timeframe.

Healthcare Stock Price Movement

Shares of Cardinal Health traded around $237.56 on Saturday. The equity has experienced notable changes since the quarter covered by the filing, reflecting broader trends across the medical distribution sector. The company's shares move between a 52-week low of $145.87 and a high of $258.30. Investors tracking valuation metrics note a trailing price-to-earnings ratio of 31.2 alongside a forward price-to-earnings ratio of 16.0.

Wall Street Analyst Updates

Wall Street firms frequently update their outlooks on the medical supplier. On October 16, 2026, UBS maintained a buy rating while lifting its price target to $295.00 from $280.00. Earlier, on August 19, 2026, RBC Capital initiated coverage with an outperform rating and a $276.00 price target. TD Cowen maintained a buy rating on August 13, 2026, raising its target to $280.00 from $275.00. JP Morgan maintained a neutral rating on August 13, 2026, lifting its target to $260.00 from $215.00. Barclays maintained an overweight rating on August 13, 2026, moving its target to $275.00 from $258.00. Citigroup maintained a buy rating on August 12, 2026, raising its target to $280.00 from $265.00. Evercore ISI Group maintained an outperform rating on August 12, 2026, lifting its target to $270.00 from $265.00. Finally, Morgan Stanley maintained an overweight rating on August 12, 2026, raising its target to $265.00 from $255.00. Overall, sixteen analysts track the stock, resulting in a strong buy recommendation and a mean price target of $270.94.

Company Operations and Corporate Focus

Headquartered in Dublin, Ohio, Cardinal Health operates as a healthcare services and products company supporting hospitals, pharmacies, ambulatory surgery centers, and clinical laboratories. The enterprise distributes pharmaceuticals and medical devices while offering customized supply chain solutions. With a workforce numbering nearly 59,000 employees, the company manages complex distribution networks across the United States and international markets.

Upcoming Financial Reports

Market participants continue monitoring institutional filings and upcoming corporate announcements for signs of longer-term trends. The company's next quarterly earnings report is scheduled for November 5, 2026. Because institutional ownership reports look backward at prior quarters, these disclosures serve as historical snapshots rather than active trading signals.